WO2000045799A3 - Use of substituted isoxazol carboxylic acids and derivatives and novel substances - Google Patents

Use of substituted isoxazol carboxylic acids and derivatives and novel substances Download PDF

Info

Publication number
WO2000045799A3
WO2000045799A3 PCT/EP2000/000517 EP0000517W WO0045799A3 WO 2000045799 A3 WO2000045799 A3 WO 2000045799A3 EP 0000517 W EP0000517 W EP 0000517W WO 0045799 A3 WO0045799 A3 WO 0045799A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
carboxylic acids
novel substances
substituted isoxazol
isoxazol carboxylic
Prior art date
Application number
PCT/EP2000/000517
Other languages
German (de)
French (fr)
Other versions
WO2000045799A2 (en
Inventor
Juergen Stoltefuss
Gabriele Braeunlich
Berthold Hinzen
Thomas Kraemer
Josef Pernerstorfer
Thomas Stuedemann
Ulrich Nielsch
Martin Bechem
Emanuel Lohrmann
Christoph Gerdes
Michael Sperzel
Klemens Lustig
Lorenz Mayr
Original Assignee
Bayer Ag
Juergen Stoltefuss
Gabriele Braeunlich
Berthold Hinzen
Thomas Kraemer
Josef Pernerstorfer
Thomas Stuedemann
Ulrich Nielsch
Martin Bechem
Emanuel Lohrmann
Christoph Gerdes
Michael Sperzel
Klemens Lustig
Lorenz Mayr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Juergen Stoltefuss, Gabriele Braeunlich, Berthold Hinzen, Thomas Kraemer, Josef Pernerstorfer, Thomas Stuedemann, Ulrich Nielsch, Martin Bechem, Emanuel Lohrmann, Christoph Gerdes, Michael Sperzel, Klemens Lustig, Lorenz Mayr filed Critical Bayer Ag
Priority to AU21100/00A priority Critical patent/AU2110000A/en
Publication of WO2000045799A2 publication Critical patent/WO2000045799A2/en
Publication of WO2000045799A3 publication Critical patent/WO2000045799A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention relates to the use of substituted isoxazol carboxylic acids and derivatives of general formula (I) in the treatment and prophylaxis of anaemia disorders. The invention also relates to novel substances of formula (Ia) and novel methods for the production thereof.
PCT/EP2000/000517 1999-02-04 2000-01-24 Use of substituted isoxazol carboxylic acids and derivatives and novel substances WO2000045799A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21100/00A AU2110000A (en) 1999-02-04 2000-01-24 Use of substituted isoxazol carboxylic acids and derivatives and novel substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904389A DE19904389A1 (en) 1999-02-04 1999-02-04 Use of substituted isoxazolecarboxylic acids and derivatives and new substances
DE19904389.2 1999-02-04

Publications (2)

Publication Number Publication Date
WO2000045799A2 WO2000045799A2 (en) 2000-08-10
WO2000045799A3 true WO2000045799A3 (en) 2002-01-24

Family

ID=7896332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000517 WO2000045799A2 (en) 1999-02-04 2000-01-24 Use of substituted isoxazol carboxylic acids and derivatives and novel substances

Country Status (5)

Country Link
AR (1) AR022469A1 (en)
AU (1) AU2110000A (en)
DE (1) DE19904389A1 (en)
GT (1) GT200000011A (en)
WO (1) WO2000045799A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2494164A1 (en) 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
CA2583177A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CN101203498A (en) 2005-05-02 2008-06-18 里格尔药品股份有限公司 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
BRPI0612028A2 (en) * 2005-06-08 2010-10-13 Novartis Ag polycyclic oxadiazoles or isodiazoles and their use as s1p receptor ligands
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
ES2400533T3 (en) 2006-09-07 2013-04-10 Actelion Pharmaceuticals Ltd. Pyridin 4-yl derivatives as immunomodulating agents
MY150661A (en) * 2006-09-08 2014-02-14 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (en) 2006-12-30 2008-07-31 Abbott Gmbh & Amp OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
ES2450750T3 (en) 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Amino-pyridine derivatives as S1P1 / EDG1 receptor agonists
CN104072489B (en) 2007-08-27 2017-07-07 达特神经科学(开曼)有限公司 Therapeutic isoxazole compounds
WO2010009775A1 (en) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
MX2010006202A (en) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses.
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
BRPI0820668A2 (en) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg 5-HALOGEN SUBSTITUTED OXINDOL DERIVATIVES AND THEIR USE TO TREAT VASOPRESSIN DEPENDENT DISEASES
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
ES2441845T3 (en) 2009-07-16 2014-02-06 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as S1P1 / EDG1 agonists
ES2544086T3 (en) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. 2-Methoxy-pyridin-4-yl derivatives
CN102329277B (en) * 2011-10-24 2013-08-07 海南霞迪药业有限公司 Method for preparing Parecoxib
EP3298008B1 (en) 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CN116535399B (en) * 2022-01-25 2024-02-27 中国药科大学 3-hydroxy-5- (isoxazol-5-yl) pyridine formyl glycine compound, preparation method, pharmaceutical composition and application

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB149877A (en) * 1919-11-22 1920-08-26 Arthur William Wells Improvements in and in connection with safety razors
EP0015140A1 (en) * 1979-02-22 1980-09-03 Monsanto Company Thermolysis of 2-(3-aryl-isoxazol-5-yl)benzoic acids, salts and halides from 3'-(aryl)-spiro(isobenzofuran-1(3H),5'(4'H)isoxazol)-3-ones
WO1993019062A1 (en) * 1992-03-24 1993-09-30 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
DE4314966A1 (en) * 1993-05-06 1994-11-10 Fahlberg List Pharma Gmbh 2-Hydroxyphenyl-substituted isoxazoles, the use thereof as pharmaceutical agents and pharmaceutical compositions containing them
WO1997019039A1 (en) * 1995-11-17 1997-05-29 Novartis Ag Solid phase synthesis of heterocyclic compounds and combinatorial compound library
EP0838543A1 (en) * 1996-09-30 1998-04-29 Lindauer Dornier Gesellschaft M.B.H Loom with devices for holding and guiding frame connecting rods
WO1998057923A1 (en) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. New production process

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB149877A (en) * 1919-11-22 1920-08-26 Arthur William Wells Improvements in and in connection with safety razors
EP0015140A1 (en) * 1979-02-22 1980-09-03 Monsanto Company Thermolysis of 2-(3-aryl-isoxazol-5-yl)benzoic acids, salts and halides from 3'-(aryl)-spiro(isobenzofuran-1(3H),5'(4'H)isoxazol)-3-ones
WO1993019062A1 (en) * 1992-03-24 1993-09-30 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
DE4314966A1 (en) * 1993-05-06 1994-11-10 Fahlberg List Pharma Gmbh 2-Hydroxyphenyl-substituted isoxazoles, the use thereof as pharmaceutical agents and pharmaceutical compositions containing them
WO1997019039A1 (en) * 1995-11-17 1997-05-29 Novartis Ag Solid phase synthesis of heterocyclic compounds and combinatorial compound library
EP0838543A1 (en) * 1996-09-30 1998-04-29 Lindauer Dornier Gesellschaft M.B.H Loom with devices for holding and guiding frame connecting rods
WO1998057923A1 (en) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. New production process
EP0994101A1 (en) * 1997-06-18 2000-04-19 Fujisawa Pharmaceutical Co., Ltd. New production process

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9434718B2 (en) 2009-07-08 2016-09-06 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions

Also Published As

Publication number Publication date
DE19904389A1 (en) 2000-08-10
GT200000011A (en) 2001-07-27
WO2000045799A2 (en) 2000-08-10
AR022469A1 (en) 2002-09-04
AU2110000A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
WO2000045799A3 (en) Use of substituted isoxazol carboxylic acids and derivatives and novel substances
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2001019780A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
EP2000136A3 (en) Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
WO2001087882A3 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
CA2416867A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
AU6287501A (en) Process for the preparation of cyclopropyl carboxylic acid esters and derivatives
UA49884C2 (en) a-hydro-carboxylic acid derivatives and their use as medicaments
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
WO2005014536A3 (en) Podophyllotoxin derivatives
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
NO20015469D0 (en) Process for the treatment of petroleum acids
AU2001277545A1 (en) Process for the production of 2-hydroxy-4-methylmercaptobutyric acid
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
AU2001242376A1 (en) Process for the preparation of 2-hydroxy-4-methylthiobutyric acid esters
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
WO2000073274A3 (en) Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors
AU3971600A (en) Use of osanetant in the production of medicaments used to treat mood disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase